SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Amazon Explores AI Content Marketplace With Media Publishers 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
YARDLEY, Pa., Nov. 17, 2017 -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ENT and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the 29th Annual Piper Jaffray Healthcare Conference November 29, 2017, at 11 am ET in New York. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will be available for 90 days following the conclusion of the event.
About Optinose®
Optinose is a specialty pharmaceutical company on a mission to improve lives with a focus on patients cared for by ear, nose and throat (ENT) and allergy specialists. The Company’s first two products rely on our patented Exhalation Delivery Systems (EDS), which are capable of deep intranasal deposition of medication. These exhalation delivery systems enable the creation of products with potential for meaningful new clinical benefits. Optinose developed its first product, Onzetra® Xsail® (sumatriptan nasal powder), through the completion of Phase 3 and subsequently out-licensed the product to Otsuka Pharmaceutical Co., Ltd. Onzetra Xsail received FDA approval and was launched in the U.S. in 2016. The Company’s second product, XHANCE (fluticasone propionate) nasal spray, is approved for the treatment of nasal polyps in patients 18 years of age and older and is in development for the treatment of chronic sinusitis. Subsequent Optinose pipeline products will aim to serve the needs of patients treated by ENT and allergy specialists and are expected to include products using EDS as well as other technologies. The Company is also currently engaged in the early development of products for neurologic orphan diseases for which the “nose-to-brain” application of an EDS may enable improved treatment. This includes OPN-300 (autism and others) and OPN-21 (narcolepsy and others). Optinose has corporate offices in the U.S., U.K. and Norway. To learn more, please visit www.optinose.com.
Optinose Media Contact
Kate Traynor, Sloane & Company
[email protected]
212.446.1871
